Researchers identify a novel NSUN2-FOSB-BCL2L1 regulatory axis in AML that drives leukemia stem cell self-renewal through m5C RNA methylation. This pathway offers a potential therapeutic target that spares normal hematopoiesis, suggesting a favorable therapeutic window for clinical translation.